Doctors are using a regulatory gap to prescribe an unauthorized peptide
Despite Health Canada’s warnings against the use of unauthorized peptides as a health and fitness shortcut, a CBC…
Lilly to file for next-gen obesity drug approval in early 2027
Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in…
The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
GLP-1 medications have been shown to improve health and offer strong value for their price, yet many insurance…
Health news round-up: coffee, ADHD prescribing, and GLP-1s and hair loss
The first cohort of MPharm pharmacist prescribers received their General Pharmaceutical Council (GPhC) registration results this week, with…
Novo’s Ozempic copy 15% cheaper, but Discovery still won’t change its position
Story audio is generated using AI Danish pharmaceutical manufacturer Novo Nordisk will launch its copy of its diabetes…
Australian regulator warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic | Health
Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and…
TGA issues new warning after finding link between GLP-1 medicines Ozempic, Wegovy, Mounjaro to eye disorder
Australia’s medicine regulator has issued a safety warning over popular weight-loss drugs like Ozempic, saying they could cause…
Trio to hold grand opening for functional medicine practice in Noblesville
At the Root, a functional medicine practice at 210 N. 10th St. Suite 30, will celebrate its grand…
Allergy medication sold nationwide recalled for potentially life-threatening mix-up with wrong pills
(Gray News) — An over-the-counter allergy medication sold nationwide is being recalled for a mix-up with another medication…
TGA issues GLP-1 RA class-wide safety update
News
Product warnings have been updated due to the high-profile treatment’s potential to cause a rare,…
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
FDA panel votes to loosen restrictions for controversial peptides
A US Food and Drug Administration (FDA) advisory panel has voted to loosen restrictions on controversial peptides that…